As part of its responsibility to prepare for public health threats, the U.S. Department of Health and Human Services' BARDA unit is seeking more effective influenza vaccines to incorporate into its pandemic strategy. Now, it's funding two projects it hopes will help the state of affairs.
Wisconsin devicemaker Stratatech scored a $247 million contract with the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to develop its skin replacement product for severe burns, giving the company a boost as it chases FDA approval for its product.
Tiny OTC-traded micro-cap Avita Medical has won backing from the U.S. Biomedical Advanced Research and Development Authority (BARDA) of its PMA approval trial for its ReCell burn treatment device. It will get $16.9 million upfront for the study and for procurement of more than 5,000 of the devices. The ongoing pivotal trial is expected to complete enrollment by the end of the this year.
Close to 18 months after AstraZeneca decided to jettison its early-stage anti-infectives division and the 180 staffers that were then working in the Massachusetts-based group, the pharma giant is stepping back up in the field, with the feds footing up to $220 million in research costs to hunt down new antibiotics.
Johnson & Johnson's Janssen struck a four-year, $28.5 million government partnership to further the development of the Ebola jab on which Janssen is collaborating with Bavarian Nordic. Janssen awarded Bavarian Nordic $9 million in a subcontract, the latter announced Tuesday.
The U.S. Biomedical Advanced Research and Development Authority (BARDA) expects that startup Velico Medical could play a role in securing the nation's blood supply. It's working to develop a technology that could be used by regional blood centers to create dried plasma and platelet products that could be rehydrated to offer an alternative to frozen versions.
While San Diego-based Pfenex's primary focus isn't on vaccines, the company gained a big backer in the space Monday with the announcement that the U.S. government has agreed to work with the biotech on its anthrax vaccine candidate for bioterror protection.
The news out of Biota Pharmaceuticals has been a steady drumbeat of defeat, setbacks and layoffs for the past two years. And this week the dirge grew even louder with the announcement that the biotech company is slashing the bulk of its staff several weeks after it lost a key government contract to support its work on a new flu drug.
PPD has signed a contract with the U.S. government's Biomedical Advanced Research and Development Authority, agreeing to design and conduct clinical trials for products that protect against bioterrorism and other public health emergencies.
Theraclone Sciences was hoping for a federal cash infusion to keep its anti-influenza antibody program rolling, but a denial from the government will force the biotech to handle Phase II on its own.